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Abstract
Background: Roux-en-Y gastric bypass (RYGB) is an effective means to achieve sustained weight loss for morbidly
obese individuals. Besides rapid weight reduction, patients achieve major improvements of insulin sensitivity and
glucose homeostasis. Dysbiosis of gut microbiota has been associated with obesity and some of its co-morbidities,
like type 2 diabetes, and major changes of gut microbial communities have been hypothesized to mediate part of
the beneficial metabolic effects observed after RYGB. Here we describe changes in gut microbial taxonomic
composition and functional potential following RYGB.
Methods: We recruited 13 morbidly obese patients who underwent RYGB, carefully phenotyped them, and had
their gut microbiomes quantified before (n = 13) and 3 months (n = 12) and 12 months (n = 8) after RYGB.
Following shotgun metagenomic sequencing of the fecal microbial DNA purified from stools, we characterized the
gut microbial composition at species and gene levels followed by functional annotation.
Results: In parallel with the weight loss and metabolic improvements, gut microbial diversity increased within
the first 3 months after RYGB and remained high 1 year later. RYGB led to altered relative abundances of 31
species (P < 0.05, q < 0.15) within the first 3 months, including those of Escherichia coli, Klebsiella pneumoniae,
Veillonella spp., Streptococcus spp., Alistipes spp., and Akkermansia muciniphila. Sixteen of these species maintained
their altered relative abundances during the following 9 months. Interestingly, Faecalibacterium prausnitzii was
the only species that decreased in relative abundance. Fifty-three microbial functional modules increased their
relative abundance between baseline and 3 months (P < 0.05, q < 0.17). These functional changes included
increased potential (i) to assimilate multiple energy sources using transporters and phosphotransferase systems,
(ii) to use aerobic respiration, (iii) to shift from protein degradation to putrefaction, and (iv) to use amino acids
and fatty acids as energy sources.
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Conclusions: Within 3 months after morbidly obese individuals had undergone RYGB, their gut microbiota
featured an increased diversity, an altered composition, an increased potential for oxygen tolerance, and an
increased potential for microbial utilization of macro- and micro-nutrients. These changes were maintained for
the first year post-RYGB.
Trial registration: Current controlled trials (ID NCT00810823, NCT01579981, and NCT01993511).
Background
Obesity affects millions of people worldwide and its preva-
lence is increasing at a pandemic level. The causes of this
complex disease include genetic predisposition, epigenetic
changes, lifestyle habits, and a range of environmental
factors [1–3]. As obesity is the main risk factor for the de-
velopment of life-threatening comorbidities such as type 2
diabetes (T2D) and coronary heart disease [4], new strat-
egies for the prevention and treatment of obesity are ur-
gently needed. Roux-en-Y gastric bypass (RYGB) surgery
is currently the most effective treatment for severely obese
individuals as it induces rapid and sustained weight loss
and a significant improvement in glucose metabolism
and insulin sensitivity [5–7]. Post-surgery effects also
include improvements in inflammatory markers [8] and
reduction of adiposity [9, 10]. Although the exact mecha-
nisms underlying these beneficial effects of RYGB are not
yet fully understood, a few factors have been suggested to
play a key role: decrease in appetite and meal size [11],
change in food preferences, anatomical rearrangement of
the gut, significant changes in the secretion of satiety-
related intestinal peptides such as glucagon-like peptide-1
(GLP-1) [12–14], and a shift in bile acid metabolism [15].
The gut microbiota has been hypothesized as a factor
linking food intake to obesity, metabolic alterations,
and intestinal inflammation [5, 16]. Some microbes
produce pro-inflammatory molecules, such as lipopoly-
saccharides, which may affect host metabolism through
proteins produced by the host to mediate the immune re-
sponse [16, 17]. Moreover, obesity has been associated with
altered gut microbiota composition [18–20], reduced
microbial diversity [21], and reduced gene richness [22].
Dietary weight loss interventions in humans have resulted
in an increase in microbial gene richness and a shift
from obese to lean microbial compositions [19, 23].
Also, diets with different proportions of fat, carbohy-
drates, and proteins have been associated with changes
in the microbiota composition in humans [24, 25]
and rodents [26–28]. Finally, the gut microbes contrib-
ute to regulation of energy homeostasis and fat storage
[16, 22, 29–31].
As RYGB leads to metabolic improvements, and meta-
bolic changes are associated with gut microbial changes,
an important open question is whether specific changes
in the gut microbiota occur following RYGB. Previous
studies investigating changes in the gut microbiota after
bariatric surgery have observed increased microbial di-
versity and altered microbial composition, primarily an
increased relative abundance of the phylum Proteobac-
teria in both humans [32–35] and rodents [36, 37].
Studies also suggest that these microbial changes may be
independent of weight loss or caloric restriction, main-
tained up to 9 years after surgery, and are not con-
founded by pre-surgery body mass index (BMI) [10, 37].
Furthermore, colonization of germ-free mice with fecal
material from RYGB-operated mice caused weight loss
and reduced adiposity, providing evidence that RYGB-
associated gut microbiota can improve host metabolism
[10, 37]. None of the studies has followed the same sub-
jects for more than 6 months, however, and it is not
clear whether gut microbial changes occur within a short
period after RYGB or gradually over a longer period.
Here we present a longitudinal shotgun-sequencing-
based metagenomics study of 13 morbidly obese patients
examined before (baseline) and 3 months (n = 12) and
1 year after RYGB (n = 8). The aim of the study was to
investigate short- and long-term changes in gut micro-
bial composition and functional potential following
RYGB-induced intestinal rearrangement and associated
changes in body weight and metabolism.
Methods
Study participants
Study participants were recruited at Hvidovre Hospital,
Denmark as a part of the bariatric surgery program. All
patients had accomplished a preoperative 8 % diet-
induced total body weight loss before inclusion and met
the Danish criteria for bariatric surgery: (i) >20 years old
and (ii) either BMI >40 kg/m2 or BMI >35 kg/m2 with
T2D/hypertension. Fecal samples were collected as a
part of three larger studies investigating the effects of
RYGB on glucose metabolism [14, 38, 39]. In total, 13
patients (five men and eight women) with available fecal
samples at baseline were included in the current study
(Additional file 1: Figure S1). Of these, seven patients
had T2D pre-surgery, one had impaired glucose tolerance,
and five had verified normal glucose tolerance. All patients
received injections of vitamin B12 as well as dietary sup-
plements post-surgery in the form of calcium, vitamin D,
and multivitamin tablets.
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Anthropometric and biochemical measurements
Participants were examined before and 3 months and
1 year after RYGB. On the day of study, participants
were examined after a 12-h overnight fast and subjected
to a liquid meal test as reported [14, 38, 39]. Blood sam-
ples were drawn in the fasting state and at eight time
points after meal intake (−10, −5, 0, 15, 30, 45, 60, 90,
120, 180, and 240 minutes relative to meal start). An-
thropometrics were measured and plasma (p) glucose,
serum (s) insulin, p-GLP-1, and glycated hemoglobin
A1c (HbA1c) were analyzed as described [14, 38, 39].
The area under the curve (AUC) for p-glucose and p-
GLP-1 was calculated using the trapezoidal method.
Stool sample collection, DNA extraction, and
metagenomic sequencing
Stool samples were collected before RYGB (n = 13) as well
as 3 months (n = 12) and 1 year (n = 8) after the surgery
(Additional file 1: Figure S1). Patients collected fresh stool
samples at home that were immediately frozen in their
home freezer at −20 °C. Frozen samples were delivered to
the hospital within 2 days using insulating polystyrene
foam containers and were stored at −80 °C until DNA
extraction.
Microbial DNA was extracted from 200 mg of frozen
stool using the International Human Microbiome Stan-
dards (IHMS) standard operating procedure 07 V2 (http://
www.microbiome-standards.org/index.php?id=254). The
concentration and quality of the extracted DNA were esti-
mated using a Qubit Fluorometer (from Thermo Scientific)
and agarose gel electrophoresis. Whole genome shotgun se-
quencing was performed on the 33 fecal samples using the
Illumina HiSeq 2000 platform and paired-end sequencing
method (2 × 100 bp). We generated, on average, 76 million
reads per sample. Reads were quality controlled, accepting
only reads with a quality trimming cutoff of 20 and a mini-
mum length of 30 bp [40]. Contaminating human DNA se-
quences were removed by screening them against the
human genome (hg19). Sample information and read qual-
ity control summary statistics are provided in Additional
file 2: Table S1.
Taxonomic profiling of fecal metagenomes
Taxonomic abundance profiles were generated by MOCAT
software [40] by aligning screened high-quality reads
(alignment length cutoff 30 and minimum 97 % sequence
identity for the option “screen”) to a database consisting of
ten universal single-copy marker genes extracted from
3496 NCBI reference genomes and 263 metagenomes [41].
We obtained abundances for 477 species-level metage-
nomic operational taxonomic units (mOTUs). Taxa were
merged if their NCBI species annotation were the same
(e.g., multiple mOTUs were annotated as Faecalibacterium
prausnitzii and Fusobacterium nucleatum).
Functional annotation and functional profiling of fecal
metagenomes
An average of 77 % high-quality reads per sample
were mapped to the recently published 9.9 million
gene catalog established from cohorts of three different
continents [42]. From this catalog we used the 42.1 %
genes annotated with the Kyoto Encyclopedia of Genes
and Genomes (KEGG) orthology [43, 44] to obtain
KEGG orthologous group profiles. Abundances were
then calculated for KEGG modules and pathways by
summing the abundances for each KEGG orthologous
group that belonged to the same module or pathway,
respectively.
Relative abundance calculation and microbial feature
selection
The abundances quantified by MOCAT at the species
level were transformed to relative abundances by divid-
ing them by the total abundance per sample, including
the high-quality reads that could not be annotated to
any reference genome or metagenome. The species
relative abundances were summarized to phylum
levels based on the NCBI taxonomy by summing the
relative abundances of all the members belonging to
the same phylum. We removed low-abundance micro-
bial features as follows. Firstly, we removed microbial
features (taxa and functional units) that were present
in <10 % of all the samples. Secondly, we removed
taxa and functional units (KEGG modules or path-
ways) whose average relative abundance across all the
samples was lower than 0.01 and 0.001, respectively.
This filtering resulted in nine phyla, 105 mOTU spe-
cies, 266 KEGG modules, and 212 KEGG pathways
for the subsequent differential analyses. Functional
units that were not prokaryotic are not discussed in
the “Results” section. When calculating fold changes,
we added a pseudo-count to the relative abundances,
which was the lowest relative abundance observed for
the entire cohort.
Addressing compositional effects
Metagenomic studies of microbial communities sample a
fraction of the total genomic content (sampling depth),
which is then sequenced at a certain sequencing depth.
Both sampling depth and sequencing depth can vary by
several orders of magnitude between samples. As absolute
microbial counts (abundances) are normally not known
and measurements depend on sampling and sequencing
depths, community compositions are represented using
relative abundances [45]. Since relative abundances are
constrained (they must sum to 1 in a given community),
they are susceptible to compositional effects where an
increase in relative abundance of one component leads
to a compositional decrease in the relative abundance
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of other components. Differential analysis based on
relative abundances thus needs careful interpretation
as compositional effects can introduce spurious differ-
ences in relative abundances while the absolute abun-
dances are not different. We developed a simple
method that enabled us to evaluate if our results were
biologically real or a consequence of studying compos-
itional data (relative abundances). The method is a
simple algorithm that tests if the fold change of each
taxon varies between time points when we exclude
each of the other taxa from the relative abundance
table. The algorithm proceeds, first, by leaving one
taxon out of the relative abundances table. Second, it
renormalizes the table by dividing the relative abun-
dances by the total sum of relative abundance to make
all the taxa relative abundances sum to 1 again. Lastly,
it calculates the fold change (log2) between time points
and performs a Wilcoxon signed-rank test for each
taxon. We repeated this process for all the taxa consid-
ered and evaluated whether our results (fold change of
microbes) were spurious or not using the least signifi-
cant P value calculated for each taxon. We have pub-
lished the R source code for this algorithm at GitHub
(https://github.com/apalleja/compositionality_test/).
Statistical analysis
The anthropometric and clinical measures have been
reported previously [14, 38], but here we present these
data as a function of time. To have a better overview of
how they globally change during the study time frame,
we projected their values at the three time points into
the principal component analysis (PCA) space. We also
measured their change normalized by months (changes
between baseline and 3 months divided by 3 and be-
tween 3 months and 1 year divided by 9). Species and
gene richness and the Shannon diversity index were
evaluated to estimate the microbial diversity before and
after RYGB.
PCA was also performed on the log10 transformed rela-
tive abundances of the mOTU species. Permutational
multivariate analysis of variance (PERMANOVA) was
used to assess the effects of the surgery (before/after), gly-
cemic status before surgery (normal glucose tolerant or
T2D), usage of metformin before surgery (five of seven
T2D patients had taken metformin before surgery), BMI,
waist/hip ratio, and postprandial p-GLP-1. We did not in-
clude in the analysis fasting p-glucose, fasting p-insulin,
HbA1c, and postprandial p-insulin and p-glucose as they
are collinear with glycemic status. We performed the ana-
lysis using the function “adonis” in the “vegan” package in
R. A distance matrix was obtained by calculating Canberra
distances among samples based on the relative abundances
of mOTU species and the permuted P value was obtained
by 10,000 permutations, as performed in a previous study
[46]. We controlled for multiple testing using Benjamini–
Hochberg (BH) false discovery rate (FDR).
We used a non-parametric statistical test to show which
microbial features (taxa and functional units) changed
their abundance significantly between time points. Since
this is a longitudinal study and samples are therefore
not independent, we used a two-sided Wilcoxon
signed-rank test, which accounts for paired samples.
The P value distribution for each statistical test was an-
alyzed to examine how our test performed across all
hypotheses. The proportion of null hypothesis on these
P value distributions was estimated by the “q value”
method (http://github.com/jdstorey/qvalue) [47], which
has been previously used in gut microbiome analysis [29,
48, 49] (these are reported in Additional file 1: Figures
S5–S10). To correct for multiple testing, we also calcu-
lated q values using the BH FDR. For each test we reported
unadjusted P values and their corresponding BH FDR q
values (q). We used a consistent unadjusted P value cutoff
of 0.05. As different feature types exhibited different distri-
butions of P values, the same unadjusted P value cutoff
leads to different estimates of FDRs and adjusted q values
for different features, ranging from q < 0.04 to q < 0.22.
Our study was underpowered (n = 13, n = 12, n = 8 in
three time points) to test hundreds of features (105 micro-
bial species and 266 microbial functions) with stringent
cutoffs (such as q < 0.05). Therefore, to avoid missing pos-
sible effects of RYGB in low-abundance microbial species
and functions, we allowed lenient FDRs corresponding to
P < 0.05, namely q < 0.08, q < 0.15, q < 0.16, q < 0.17, and q
< 0.22. However, to ensure that results are interpreted
with caution, we explicitly reported the upper bounds for
number of false positives when the FDR was above 10 %.
We did discard microbial changes in three cases when
P < 0.05 corresponded to extremely high FDRs, namely
q > 0.86, q > 0.91, and q > 0.99. For completeness we
also report the q values from the Storey “q value”
method in Additional file 1: Tables S3 and S4. They are
generally quite similar to the BH FDR q values. All the
data analysis and statistical testing were performed with R
(version 3.2.0; http://www.R-project.org/).
Results and discussion
Gut microbial diversity increases after RYGB in parallel
with metabolic improvements
We have previously reported that, 3 months after RYGB
surgery, BMI, fasting p-glucose, fasting s-insulin, and
HbA1c significantly decreased, while postprandial p-GLP-
1 secretion significantly increased in the subjects studied
here [14, 38, 39]. The projection of all the phenotypic data
considered in our study on the principal component space
showed an overall change in anthropometric and clin-
ical markers after RYGB (Additional file 1: Figure S2).
We investigated whether the metabolic improvements
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and gut microbial changes occurred within short-term
(within 3 months) or long-term following RYGB using
samples collected 3 months and 1 year after RYGB.
Additionally, to study the role of gut microbiota in rela-
tion to the metabolic improvements, we chose to investi-
gate BMI, fasting p-glucose, postprandial p-glucose, and
postprandial p-GLP-1 as indicators of health status after
RYGB. BMI, fasting p-glucose, and postprandial p-GLP-
1 differed between baseline and 3 months (Additional
file 1: Figure S3; Wilcoxon signed-rank test; P = 0.00049,
P = 0.0042, and P = 0.00098, respectively). Only BMI and
fasting p-glucose differed between 3 months and 1 year
after RYGB (Additional file 1: Figure S3; Wilcoxon signed-
rank test; P = 0.016 and P = 0.047, respectively). However,
when we normalized the changes by the number of
months within each time interval, we observed that the
shift towards a healthier metabolism occurred mainly
within the first 3 months after RYGB (Fig. 1a). Though
these improvements were maintained during the following
9-month period, the rate of improvement was markedly
lower.
We estimated gut microbial species compositions using
the species-level mOTU approach, based on single-copy
phylogenetic marker genes [41]. As previous studies have
shown a positive association between a healthy metabolic
state and increased microbial diversity and gene richness
[22, 23], we first estimated the microbial alpha-diversity
using three measures: species richness, species Shannon
index, and gene richness. Compared with baseline, the
Shannon index at the species level showed a weak ten-
dency to increase 3 months and 1 year after RYGB
(Additional file 1: Figure S4a; Wilcoxon signed-rank
test; P = 0.077 and P = 0.15, respectively). While species
richness was higher 3 months after RYGB and this higher
richness was maintained at 1 year (Wilcoxon signed-rank
test; P= 0.0096 and P= 0.0078, respectively; Additional file 1:
Figure S4b), gene richness exhibited a tendency to increase
only after 1 year (Wilcoxon signed-rank test; P = 0.078;
a) b)
Fig. 1 Metabolic and microbial diversity improvements during a 1-year period after RYGB. Box plots represent features measured at the three
different time points. Lines connect the measures from the same subject. For each pairwise comparison between time points, the P value of the
Wilcoxon signed-rank test (P), the difference between the medians (Δ), and difference between medians normalized by time difference (Δ′) are
denoted. a Host metabolism improvements. Postprandial glucose and GLP-1 levels were calculated as area under the curve during a standardized
meal test. b Microbial species diversity improvements
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Additional file 1: Figure S4c). The discrepancy between spe-
cies richness and gene richness could be due to lack of
power when using n = 12 samples. When we normalized
the changes in species richness and Shannon index by the
number of months (Fig. 1b), we observed that most
changes occurred within the first 3 months and were
merely maintained during the last 9 months. Thus, the mi-
crobial diversity improvements mirrored the trends of
metabolic improvements.
Persistent changes in the gut microbial composition
induced by RYGB
We visualized the changes in overall gut microbial spe-
cies composition induced by RYGB using a principal
component analysis of the log-transformed relative
abundances (Fig. 2), which showed a clear separation
between baseline samples and those after RYGB. Such
separation could not be observed between 3-month and
1-year samples, suggesting that most of the changes in
microbial composition occurred within 3 months and
those changes were maintained up to 1 year. RYGB in-
duces physiological and metabolic changes in the sub-
jects, which may also be contributing to the changes in
the microbiome composition. In order to evaluate this,
we performed a permutational analysis of variance
(PERMANOVA) test to quantify the variance explained
by RYGB as well as other physiological and metabolic
parameters. RYGB surgery, T2D status (before surgery),
metformin usage (before surgery), p-GLP-1 levels (at each
time point), and BMI (at each time point) explained the
variation in species composition (P < 0.05; q < 0.06;
Additional file 2: Table S2). As we included both normal
glucose tolerant and T2D patients, our PERMANOVA re-
sults suggest that RYGB alters the gut microbial compos-
ition in both groups. Our finding on the effect of T2D
status agrees with previous reports on altered gut micro-
bial composition in T2D patients [29, 30]. It is interesting
to note that baseline T2D status had an effect on gut mi-
crobial composition up to 1 year after RYGB. At baseline,
most T2D patients (five out of seven) in the cohort were
taking metformin, which has recently been reported to
alter gut microbial composition and confound the gut mi-
crobial signatures associated with T2D [46]. Therefore, we
cannot distinguish the microbial changes due to T2D sta-
tus from microbial changes induced by taking metformin.
Previous studies have hypothesized that GLP-1 secretion
can be stimulated by bacterial metabolites such as short
chain fatty acids through GPR41/43-dependent mecha-
nisms [50], which could explain the association between
p-GLP-1 levels and gut microbial composition. Finally,
PERMANOVA results suggest that BMI could explain the
variation in gut microbial composition but to a lesser ex-
tent than the surgery. Previous studies have reported that
the gut microbial changes identified by them were not
confounded by BMI [10, 37]. Our results do not contra-
dict their conclusions but suggest that, in our cohort, BMI
can explain some additional variation in gut microbial
composition beyond what is explained by RYGB.
We next investigated compositional changes in individual
taxa following RYGB using Wilcoxon signed-rank tests on
relative abundances. Verifying taxonomic changes using
relative abundance is susceptible to compositional effects,
where an isolated increase in absolute abundance of just one
taxon will lead to a dissipated decrease in relative abundance
of all other taxa as the relative abundances must always sum
to 1 [45]. Although there is an ongoing discussion about
how to differentiate compositionality-induced changes from
real changes [45, 51–53], this is not commonly addressed in
microbiome studies. We developed a procedure to assess
whether compositionality had influenced our results. When
a taxon exhibited a significant difference in relative abun-
dance between two time points, we verified whether this
difference was a compositional effect due to a difference
in another taxon. We tested if the former would still ex-
hibit a difference if the latter was never observed in any of
the samples. By systematically repeating this procedure for
all other taxa and evaluating the least significant P value,
we could discard spurious differences arising due to com-
positional effect (see “Methods” for details).
At the phylum level, compared with baseline, Proteo-
bacteria and Fusobacteria showed an increase in relative
abundance 3 months after RYGB (Wilcoxon signed-
rank test, P < 0.05, q < 0.04; Additional file 2: Table S3).
Fig. 2 Gut microbial community differences induced by RYGB.
Principal component analysis based on log transformed mOTU
species abundances shows a clear separation between pre-RYGB
and post-RYGB fecal samples. The variation explained by each com-
ponent is shown on its axis. MO months, Y year
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The same two phyla exhibited increased abundance
levels after 1 year compared with baseline (P < 0.05, q <
0.08; Additional file 2: Table S4) and we did not observe
any significant phylum level changes between 3 months
and 1 year (q > 0.91). At the species level, 31 species
changed their relative abundance within the first
3 months (Wilcoxon signed-rank test; P < 0.05, q < 0.15,
suggesting that up to five species could be false posi-
tives; Fig. 3; Additional file 1: Figure S5; Additional file
2: Table S3). Nineteen species changed between base-
line and 1 year (P < 0.05, q < 0.22, suggesting that up to
five could be false positives; Fig. 3; Additional file 1:
Figures S6; Additional file 2: Table S4), including 16 of
the 31 species that changed within the first 3 months.
However, we did not observe significant changes in species
abundances when comparing the gut microbiota compos-
ition at 3 months and 1 year after RYGB (Wilcoxon
signed-rank test; q > 0.99; Additional file 1: Figure S7),
which provides further evidence that the remodeling of the
microbial community occurred mainly within the first
3 months after the surgery. Figure 3 shows the RYGB-
associated fold changes for these 31 differentially abundant
species. When we performed the test for compositional ef-
fect, only four of these species lost their significance (P >
0.05) when another species was considered absent (Fig. 3),
suggesting that most taxonomic changes reported here are
not affected by compositionality. Most of the 31 species,
including two affected by compositionality (Actinomyces
odontolyticus and F. nucleatum), exhibited a marked differ-
ence in their fold change when Prevotella copri was consid-
ered absent. The genus Prevotella is the main driver of the
Prevotella enterotype [54] and exhibits a bimodal distribu-
tion, with high relative abundance in some individuals and
a low relative abundance in others [55], which explains
why simulating the absence of P. copri leads to marked
changes in the relative abundance of other species.
Escherichia coli and Klebsiella pneumoniae showed a
dramatic increase after RYGB (Fig. 3). Previous studies
have reported the increase of E. coli after RYGB and have
pointed to its higher efficiency to harvest energy during
Fig. 3 Changes in individual gut microbial species following RYGB. Median fold changes in relative abundances of 31 mOTU species that
changed between baseline and 3 months (3MO, bottom panel), and 16 among these that changed between baseline and 1 year (1Y, top panel)
after RYGB. For each bacterial species, the cloud of circles represents all fold changes calculated when excluding one other species from the
abundance table. The horizontal grey lines at −1 and 1 mark when the microbes halved or doubled their relative abundance. Exclusion of
Prevotella copri substantially altered the fold change for many species and the corresponding fold change is denoted as an empty triangle. The
colored band in each panel shows the statistical significance of Wilcoxon signed-rank tests after our compositionality test. Asterisks mark species
that have already been reported in previous studies
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host starvation status, giving them an advantage in the
post-RYGB starvation-like condition during the first
months after the surgery [34]. Ten species belonging to
the genus Streptococcus, four from Veillonella, two from
Alistipes, Bifidobacterium dentium, Enterococcus faecalis,
F. nucleatum, and Akkermansia muciniphila also in-
creased their abundance after RYGB (Fig. 3). Our results
agree with previous findings that A. muciniphila, a
mucin-degrading bacterium, is associated with reduc-
tion in adiposity, inflammation, glucose intolerance,
and body fat mass [56]. The increase in aero-tolerant
Proteobacteria, including Streptococcus spp., E. coli, K.
pneumoniae, and E. faecalis, might result from a higher
presence of oxygen in distal parts of the gut due to the
anatomical rearrangements as reported previously [35,
57]. Changes in pH after RYGB may also affect these
aero-tolerant anaerobic microbes by inducing changes
in the redox potential of the gut [58]. Furthermore, a
decrease in acid secretions due to the reduced size of
the stomach could make the gastric barrier less strin-
gent for oral microbiota such as Streptococcus spp., to-
gether with F. nucleatum, B. dentium and a few
Veillonella spp., which are metabolically dependent on
Streptococcus spp. in oral biofilms [59]. The only spe-
cies that decreased after RYGB in our study was the
butyrate-producing F. prausnitzii, which is surprising
as it has been associated with beneficial effects on host
metabolism and negatively correlated with inflamma-
tion markers [60]. A previous study using metagenomic
sequencing has also reported a post-RYGB decrease of
F. prausnitzii in six obese T2D patients [35]. On the
contrary, another study using quantitative PCR re-
ported that, in obese T2D patients, F. prausnitzii
showed a trend to increase 3 months after RYGB and
stayed at the increased level 6 months after RYGB [33].
The latter study also reported that, in obese non-diabetic
individuals, F. prausnitzii decreased significantly 3 months
after RYGB and returned back to basal levels 6 months
after RYGB. Here we observed that F. prausnitzii de-
creases following RYGB for most of the diabetic and
non-diabetic patients. Taken together, our study has
reproduced six previously observed species-level changes
in obese individuals after RYGB (E. coli, K. pneumoniae,
Veillonella dispar, Veillonella parvula, E. faecalis, and F.
prausnitzii). Previous studies have also reported changes
in the relative abundance of Acinetobacter spp., Citrobac-
ter spp., Clostridium spp., Enterobacter spp., Pseudomonas
spp., Shigella spp., Staphylococcus spp., Vibrio spp., and
Yersinia spp. [10, 32, 35], which we could not verify in our
study (see Additional file 2: Table S5 for the full list of
species). We also observed an increase in Alistipes spp.,
Streptococcus spp., two other Veillonella spp., and A.
muciniphila that are unique to this study (see Additional
file 2: Table S5 for the full list of species).
Altered microbial functions after RYGB
To characterize the changes in functional potential of mi-
crobes to adapt to the gut rearrangement after RYGB, we
estimated the relative abundances for KEGG modules and
pathways in each sample. We found 62 KEGG modules
that changed in relative abundance between baseline and
3 months after RYGB (Wilcoxon signed-rank test, P <
0.05, q < 0.17, suggesting that up to 11 modules could be
false positives; Additional file 1: Figure S8; Additional file
2: Table S3), and 63 KEGG modules that changed between
baseline and 1 year (Wilcoxon signed-rank test, P < 0.05,
q < 0.16, suggesting that up to ten could be false positives;
Additional file 1: Figure S9; Additional file 2: Table S4),
while we did not observe significant changes between
3 months and 1 year (q > 0.86; Additional file 1: Figure
S10). Most of these changes (53 out of 62 in the former
and 56 out of 63 in the latter) reflected an increase in rela-
tive abundance over time (Fig. 4), which may reflect the
increased species richness after RYGB. Of the 53 modules
that increased their abundance within the first 3 months,
44 sustained it for a year. Thus, the functional changes
mirrored the taxonomic changes, where most changes
had occurred during the first 3 months and were merely
maintained during the following 9 months.
Among the KEGG modules that increased their abun-
dance after RYGB, we observed several nutrient trans-
port systems (Fig. 4). Morbidly obese patients who have
undergone bariatric surgery have a smaller stomach
pouch and their food intake skips the duodenum, which
causes malabsorption of essential vitamins, minerals,
and drugs [61]. To compensate for this malnutrition, pa-
tients follow a diet rich in proteins and take calcium,
iron, and multivitamin supplements (see “Methods”).
We observed an increased potential for microbial trans-
port systems of thiamine, vitamin B12, manganese, iron,
and zinc (Fig. 4), which could reflect the increased avail-
ability of these compounds that are also essential for
microbes. Transport systems of phosphonates were also
increased after RYGB. Some bacteria such as E. coli and
Klebsiella spp. can utilize these compounds as an alter-
native source of phosphorus by breaking their C–P
bonds [62].
There was also an increased abundance of transport
systems for monosaccharides such as D-xylose, rham-
nose, D-allose, and L-arabinose after RYGB. In E. coli,
the presence of L-arabinose in the absence of glucose
dynamically activates the operon that drives the catab-
olism of arabinose [63]. Arabinose is present in rice,
wheat, beans, oats, or plant polysaccharides. Thus, our
finding may reflect changes in diet, for example, a shift
in food preferences towards lower-calorie-dense foods
as reported after RYGB [64–66].
Other transport systems that increased in abundance
after RYGB are the phosphotransferase systems (PTS;
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Fig. 4), which are only found in bacteria. PTS catalyze
the transport and phosphorylation of numerous mono-
saccharides, disaccharides, amino sugars, polyols, and
other sugar derivatives into the bacterial cell. Their in-
crease could be attributed to an increased ability of mi-
crobes to assimilate all available sugars to compensate
for the reduced dietary intake. Figure 4 also shows the
increased potential of amino acid uptake, suggesting
the utilization of amino acids as a source of energy, and
an increased potential for beta-oxidation of fatty acids,
indicating the utilization of these fatty acids as a source
of energy.
The KEGG module for cytochrome c oxidase complex
and the module for prokaryotic biosynthesis of ubiquin-
one also increased in abundance after RYGB. The former
is the last enzyme of the electron transport chain in both
bacteria and eukaryotic mitochondria. Ubiquinone, known
as coenzyme Q10, also plays a crucial role as an electron
carrier in the electron transport chain. The increased rela-
tive abundance of these two modules together with the
increase of facultative anaerobes such as E. coli, K. pneu-
moniae, E. faecalis, and Streptococcus spp. suggest a shift
towards aerobic respiration among the facultative anaer-
obes to benefit from a higher presence of dissolved oxygen
in the hindgut after RYGB [57]. Electron transport
chains are major sites of premature electron leakage to
oxygen, generating superoxide and potentially resulting
in increased oxidative stress. Post-RYGB, we observed
an increased abundance of a module encoding glutathi-
one biosynthesis from glutamate and an increased
abundance of transport systems of both glutamate and
glutathione (Fig. 4). In bacteria, glutathione, in addition
to its key role in maintaining the proper oxidation state
of protein thiols, also protects the cell from oxidative
and osmotic stress [67]. Thus, the increased capacity in
glutathione biosynthesis and transport suggests that the
gut microbes may be using glutathione to combat oxi-
dative stress.
Intriguingly, following RYGB we observed an increase
in abundance of two KEGG modules involved in putres-
cine transportation (Fig. 4). Although protein digestion
is not impaired after RYGB [68], the increased potential
for putrescine transportation might indicate a certain
level of putrefaction in the colon, as other authors have
hypothesized when studying the fecal metabolic profiles
after RYGB in a non-obese rat model [36]. Fast pouch
emptying and a delayed small intestinal transit time have
been reported for RYGB patients [69]. Reduction of
gastric acid secretion after surgery [70, 71], which plays
a key role in protein digestion by activating proteolytic
enzymes, might cause more incompletely digested pro-
teins to reach the colon. Under these circumstances, a
longer intestinal transit time could provide enough time
for microbes to catabolize these proteins, resulting in the
production of polyamines such as putrescine [36, 72],
which is involved in key functions such as DNA and
Fig. 4 Microbial functional changes following RYGB. Box plots represent fold changes (log2) in the 53 KEGG modules that increased in relative
abundance between baseline and 3 months (3MO, left panel) and 44 among these that increased between baseline and 1 year (1Y, right panel)
after RYGB. The different KEGG functional categories are represented by different colors and grouped together when possible with corresponding
labels at the right side of the plot. PTS phosphotransferase systems, GABA gamma-aminobutyric acid
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membrane stabilization but becomes toxic at high doses
and can even produce carcinogenic nitrosamines [73].
Putrescine has been found in elevated concentrations in
fecal samples post-RYGB in rats [36]. Enterobacteriaceae
spp. such as E. coli or Klebsiella spp. can produce putres-
cine by decarboxylation of the amino acids ornithine and
arginine [73], of which we also observed an increased
transportation potential after RYGB (Fig. 4). The increased
capacity to transport putrescine could also reflect the
antioxidant and anti-inflammatory properties of this
polyamine for microbes when oxidative stress increases
[74–76]. Microbial processing of putrescine can pro-
duce gamma-aminobutyric acid (GABA) [77], which is
an inhibitory neurotransmitter of the mammalian cen-
tral nervous system and has been found increased in
fecal samples after RYGB in a rat model [36]. This
neurotransmitter is thought to stimulate the intestinal
cells to release GLP-1 [78, 79]. Increased levels of GLP-
1 observed after RYGB in our cohort (Fig. 1; Additional
file 1: Figure S3) is consistent with this link. The increase
in GLP-1 can, in turn, stimulate the biosynthesis of GABA
via pancreatic beta-cells [80]. An increased capacity for
GABA biosynthesis and GABA shunt (closed loop to pro-
duce and maintain the supply of GABA) pathways
observed after RYGB (Fig. 4) provides further evidence for
this metabolic path after RYGB.
Conclusions
We recruited morbidly obese human patients undergoing
RYGB, performed a longitudinal study of the effects of
RYGB on gut microbiota, and compared the short-term
effects (after 3 months) with the long-term effects (after
1 year). Our analyses showed an increased gut microbial
diversity and an altered microbial composition in conjunc-
tion with the metabolic improvements seen after RYGB.
Most of these changes occurred within the first 3 months
and were maintained during the following 9 months.
Although we cannot prove a causal role for gut micro-
bial changes in relation to the metabolic improvements,
a recent study has shown that transferring post-RYGB
microbiota from humans to germ-free mice leads to fat
mass regulation [10], suggesting that the altered microbiota
could contribute to metabolic changes. Thus, our study
opens up new possibilities for thorough characterization of
gut microbial changes immediately following RYGB in
order to verify their contribution to metabolic health
improvement.
Fig. 5 A model of gut microbial changes following RYGB. Blue boxes show inferred changes in microbial features (functional potential or taxonomic),
while green boxes show the effects induced by RYGB either in the gut or in the host metabolism. Black boxes indicate hypotheses based on
our data or other studies. Arrows connect shifts that are related. Since we did not measure inflammation markers we do not report an increase
or decrease in inflammation, but we connect it to an observed change based on existing literature. All features shown here exhibited changes
3 months after RYGB and most maintained the changes up to 1 year after RYGB. Asterisks denote features that did not maintain the changes
1 year after RYGB
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We also developed procedures to rule out spurious
changes in microbial relative abundance due to com-
positional effects. Microbial changes observed here
were RYGB-specific and different from changes due to
weight loss interventions [26]. Our interpretation of
data is in accordance with recent observations in mice
[37]. Collectively the available evidence suggests that
the microbial changes after RYGB are more driven by
the intestinal rearrangement rather than weight loss.
Proteobacteria and Fusobacteria increased their relative
abundance and the butyrate-producer F. prausnitzii de-
creased after RYGB. The increase in abundance of
aero-tolerant bacteria from the phylum Proteobacteria,
together with the increased abundance of genes encoding
key components in the electron transport chain, indicated
adaptation to a higher presence of oxygen in the distal gut
after RYGB, as previously reported [32, 35, 57] (Fig. 5). In-
creased abundance of various systems of transportation
and uptake of vitamins, minerals, organic compounds,
simple sugars, and amino acids could suggest an increased
potential of microbes to assimilate essential compounds
and all possible energy substrates as compensatory mech-
anisms to counteract reduced food intake after RYGB. We
observed an increased microbial potential to transport pu-
trescine, which could even contribute to a higher secretion
of GLP-1 via GABA biosynthesis (Fig. 5). In future studies,
it would also be relevant to measure the fecal putrescine
content to assess the extent to which protein putrefaction
occurs after RYGB and to relate this measure to any po-
tential health risk that may be caused by this toxin.
By identifying swift and consistent changes that oc-
curred within 3 months and were maintained for a year in
morbidly obese humans, we have modeled the persistent
gut microbial changes induced by RYGB (Fig. 5). Further
studies characterizing such changes at a finer time scale
immediately after surgery will shed more light on the dy-
namic adaptation of gut microbiota to RYGB and their
role in metabolic improvements.
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